Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.

Journal of the American College of Surgeons - 1 Jul 2024

Darabi Sourat, Adeyelu Tolulope, Elliott Andrew, Sukari Ammar, Hodges Kurt, Abdulla Farah, Zuazo Carlos E, Wise-Draper Trisha, Wang Thomas, Demeure Michael J

Abstract excerpt

BACKGROUND: About 75% of medullary thyroid cancers (MTCs) are sporadic with 45% to 70% being driven by a RET mutation. Selpercatinib is an approved treatment for RET-mutated (mut RET ) MTC; however, treatments are needed for wild-type RET MTC (wt RET ). Genomic alterations and transcriptomic signatures of wt RET MTC may reveal new therapeutic insights. STUDY DESIGN: We did a retrospective analysis of MTC samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinases

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins c-ret

Share to Thyroid Neoplasms

Share to Transcriptome

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 38651727
DOI: 10.1097/XCS.0000000000001098
PMCID: PMC11168784

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Transcriptomic Landscape of RET Wild-Type Medullary Thyroid Cancer and Potential Use of Mitogen-Activated Protein Kinase-Targeted Therapy.PMID 38651727Read ↗

RET Alterations Differentiate Molecular Profile of Medullary Thyroid Cancer.Semantic proximity Read ↗

Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors.Semantic proximity Read ↗

Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor SamplesSemantic proximity Read ↗

Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.Semantic proximity Read ↗

Comprehensive Immune Profiling of Medullary Thyroid Cancer.Semantic proximity Read ↗

Integrated proteogenomic characterization of medullary thyroid carcinomaSemantic proximity Read ↗

Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.Semantic proximity Read ↗

Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapySemantic proximity Read ↗

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.Semantic proximity Read ↗

Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.Semantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Comparative multi-omics analysis uncovers contrasting molecular profiles of canine and human thyroid carcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.